59 2.1. Résultats in vitro, p.60 ,
Glioblastoma in adults, Critical Reviews in Oncology/Hematology, vol.67, issue.2, pp.139-152, 2008. ,
DOI : 10.1016/j.critrevonc.2008.02.005
Epidemiology and etiology of gliomas, Acta Neuropathologica, vol.43, issue.1, pp.93-108, 2005. ,
DOI : 10.1007/s00401-005-0991-y
Genetic Pathways to Glioblastoma: A Population-Based Study, Cancer Research, vol.64, issue.19, pp.6892-6899, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1337
Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas, Journal of Neuropathology & Experimental Neurology, vol.64, issue.6, pp.479-489, 2005. ,
DOI : 10.1093/jnen/64.6.479
Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma, British Journal of Cancer, vol.6, issue.1, pp.108-114, 2006. ,
DOI : 10.1006/gyno.1997.4783
Chemotherapy in adult high-grade glioma : a systematic review and meta-analysis of individual patient data from 12 randomised trials, Lancet, vol.359, pp.1011-1029, 2002. ,
Perfusion MR Imaging of Brain Neoplasms, American Journal of Roentgenology, vol.174, issue.4, pp.1147-57, 2000. ,
DOI : 10.2214/ajr.174.4.1741147
Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas, Laboratory Investigation, vol.13, issue.1, pp.65-72, 2000. ,
DOI : 10.1038/labinvest.3780009
Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25, Oncogene, vol.10, pp.2243-2246, 1995. ,
Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades, Genes, Chromosomes and Cancer, vol.77, issue.1, pp.9-15, 1998. ,
DOI : 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1
p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas, Brain Pathology, vol.18, issue.2 ,
DOI : 10.1111/j.1750-3639.2001.tb00388.x
Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas, Acta Neuropathologica, vol.94, issue.4 ,
DOI : 10.1007/s004010050711
Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials, JNCI Journal of the National Cancer Institute, vol.85, issue.9, pp.704-710, 1993. ,
DOI : 10.1093/jnci/85.9.704
Age and radiation response in glioblastoma multiforme ,
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy, Journal of Neurosurgery, vol.100, issue.1, pp.41-47, 2004. ,
DOI : 10.3171/jns.2004.100.1.0041
Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas, Neurosurgery, vol.41, issue.5, pp.1028-1064, 1997. ,
The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas ,
Debulking or biopsy of malignant glioma in elderly people - a randomised study, Acta Neurochirurgica, vol.145, issue.1 ,
DOI : 10.1007/s00701-002-1030-6
Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma, Oncology, vol.76, issue.3, pp.184-193, 2009. ,
Glioblastoma treatment in 2010, Rev Med Brux, vol.30, issue.5, pp.496-505, 2009. ,
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO), British Journal of Cancer, vol.2, issue.7, pp.1047-51, 2007. ,
DOI : 10.1126/science.1101637
A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM), Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.2016
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors, New England Journal of Medicine, vol.353, issue.19, pp.2012-2024, 2005. ,
DOI : 10.1056/NEJMoa051918
Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib, JNCI Journal of the National Cancer Institute, vol.97, issue.12, pp.880-887, 2005. ,
DOI : 10.1093/jnci/dji161
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma, Annals of Oncology, vol.20, issue.9, pp.1596-1603, 2009. ,
DOI : 10.1093/annonc/mdp032
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma, Cytokine & Growth Factor Reviews, vol.15, issue.4, pp.275-86, 2004. ,
DOI : 10.1016/j.cytogfr.2004.03.002
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series, Annals of Oncology, vol.16, issue.10, pp.1702-1710, 2005. ,
DOI : 10.1093/annonc/mdi317
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme, Journal of Clinical Oncology, vol.23, issue.36 ,
DOI : 10.1200/JCO.2005.03.2185
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas, Acta Neuropathologica, vol.17, issue.6, pp.467-70, 2004. ,
DOI : 10.1007/s00401-004-0929-9
Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer, Journal of Clinical Oncology, vol.22, issue.19, pp.3950-3957, 2004. ,
DOI : 10.1200/JCO.2004.10.037
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer, Journal of Clinical Oncology, vol.22, issue.8, pp.1430-1438, 2004. ,
DOI : 10.1200/JCO.2004.10.112
Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells, Journal of Pharmacology and Experimental Therapeutics, vol.319, issue.3, pp.1070-1080, 2006. ,
DOI : 10.1124/jpet.106.108621
AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma, Cancer Research, vol.66, issue.17, pp.8722-8730, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-0284
Enhanced Protein Kinase C Activity Correlates with the Growth Rate of Malignant Gliomas in Vitro, Neurosurgery, vol.29, issue.6 ,
DOI : 10.1227/00006123-199112000-00013
LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice, Cancer Chemotherapy and Pharmacology, vol.53, issue.2, pp.133-140, 2004. ,
DOI : 10.1007/s00280-003-0713-x
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study, Neuro Oncol, vol.12, issue.6, pp.608-621, 2010. ,
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma, J Clin Oncol, vol.28, issue.7, pp.1168-74, 2010. ,
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas, Journal of Neuro-Oncology, vol.7, issue.3, pp.215-237, 2005. ,
DOI : 10.1007/s11060-004-1718-y
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells, Molecular Cancer Therapeutics, vol.5, issue.6, pp.1504-1514, 2006. ,
DOI : 10.1158/1535-7163.MCT-06-0091
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma, J Neurooncol, vol.96, issue.2, pp.219-249, 2010. ,
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study, Journal of Clinical Oncology, vol.23, issue.23, pp.5294-5304, 2005. ,
DOI : 10.1200/JCO.2005.23.622
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme, Investigational New Drugs, vol.19, issue.4, pp.357-361, 2005. ,
DOI : 10.1007/s10637-005-1444-0
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM), Journal of Neuro-Oncology, vol.66, issue.1, pp.99-105, 2009. ,
DOI : 10.1007/s11060-008-9741-z
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature, vol.359, issue.6398 ,
DOI : 10.1038/359845a0
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, vol.362, issue.6423, pp.841-844, 1993. ,
DOI : 10.1038/362841a0
Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma, Int J Radiat Oncol Biol Phys, vol.40, issue.2, pp.297-302, 1998. ,
A multicenter phase I trial of combination therapy with interferon-? and temozolomide for high-grade gliomas (INTEGRA study): the final report, J Neurooncol, vol.104, issue.2, pp.573-580, 2011. ,
Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-?? for supratentorial glioblastoma: Results of RTOG 9710, International Journal of Radiation Oncology*Biology*Physics, vol.66, issue.3, pp.818-842, 2006. ,
DOI : 10.1016/j.ijrobp.2006.05.021
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res, vol.60, pp.1306-1311, 2000. ,
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma, Cancer, vol.83, issue.2, pp.329-367, 2005. ,
DOI : 10.1002/cncr.20776
Characterization of Endothelin Receptors in Human Brain Cortex, Gliomas, and Meningiomas, Journal of Cardiovascular Pharmacology, vol.26, pp.408-419, 1995. ,
DOI : 10.1097/00005344-199506263-00120
Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma, Neuro-Oncology, vol.10, issue.4, pp.617-623, 2008. ,
DOI : 10.1215/15228517-2008-013
HISTONE-DEACETYLASE INHIBITORS: NOVEL DRUGS FOR THE TREATMENT OF CANCER, Nature Reviews Drug Discovery, vol.19, issue.4, pp.287-99, 2002. ,
DOI : 10.1074/jbc.274.44.31127
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study, Journal of Clinical Oncology, vol.27, issue.12, pp.2052-2060, 2009. ,
DOI : 10.1200/JCO.2008.19.0694
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma, Neuro-Oncology, vol.14, issue.1, pp.93-100, 2012. ,
DOI : 10.1093/neuonc/nor187
Phase I trial of bortezomib in adults with recurrent malignant glioma, Proc Am Soc Clin Oncol, vol.24, p.1567, 2006. ,
Adenovirus-mediated p53 Gene Therapy for Human Gliomas, Neurosurgery, vol.45, issue.5, pp.1093-1104, 1999. ,
DOI : 10.1097/00006123-199911000-00016
The Dendritic Cell System and its Role in Immunogenicity, Annual Review of Immunology, vol.9, issue.1 ,
DOI : 10.1146/annurev.iy.09.040191.001415
Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma, Cancer Research, vol.64, issue.14, pp.4973-4979, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-3505
Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial, Clinical Cancer Research, vol.11, issue.11, pp.4160-4167, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0120
Postoperative Adjuvant Dendritic Cell-Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme, Clinical Cancer Research, vol.14, issue.10, pp.3098-104, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-4875
Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiform, Curr Opin Mol Ther, vol.12, pp.741-54, 2010. ,
Production of transforming growth factor beta by human T ! ! 90 ! lymphocytes and its potential role in the regulation of T cell growth, J Exp Med, vol.163, issue.5, pp.1037-1050, 1986. ,
Results of a phase Iib active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma, ASCO Meeting Abstracts, vol.26, issue.15, p.2076, 2008. ,
Trabedersen Glioma Study Group Targeted therapy for highgrade glioma with the TGF-?2 inhibitor trabedersen: results of a randomized and controlled phase IIb study, Neuro Oncol, vol.13, issue.1, pp.132-174, 2011. ,
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas ,
Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts, Mol Cancer Ther, vol.1, issue.12, pp.999-1007, 2002. ,
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma, Neuro-Oncology, vol.12, issue.8, pp.871-81, 2010. ,
DOI : 10.1093/neuonc/nop054
Molecularly targeted therapy for malignant glioma, Cancer, vol.444, issue.1, pp.13-24, 2007. ,
DOI : 10.1002/cncr.22741
BCL-2 FAMILY: Regulators of Cell Death, Annual Review of Immunology, vol.16, issue.1, pp.395-419, 1998. ,
DOI : 10.1146/annurev.immunol.16.1.395
Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade, Cell, vol.91, issue.4, pp.479-89, 1997. ,
DOI : 10.1016/S0092-8674(00)80434-1
Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL., Molecular and Cellular Biology, vol.17, issue.12, pp.7040-7046, 1997. ,
DOI : 10.1128/MCB.17.12.7040
BH3 Domain of BAD Is Required for Heterodimerization with BCL-XL and Pro-apoptotic Activity, Journal of Biological Chemistry, vol.272, issue.39, pp.24101-24105, 1997. ,
DOI : 10.1074/jbc.272.39.24101
BCL-2 in the crosshairs: tipping the balance of life and death, Cell Death and Differentiation, vol.3, issue.8, pp.1339-50, 2006. ,
DOI : 10.1073/pnas.87.10.3660
Recent advances with liposomes as pharmaceutical carriers, Nature Reviews Drug Discovery, vol.103, issue.2 ,
DOI : 10.1081/LPR-120017488
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Letters, vol.3, issue.1, pp.235-238, 1990. ,
DOI : 10.1016/0014-5793(90)81016-H
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, Journal of Controlled Release, vol.65, issue.1-2, pp.271-84, 2000. ,
DOI : 10.1016/S0168-3659(99)00248-5
Production of Recombinant Proteoliposomes for Therapeutic Uses, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00821163
Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients, Neuro-Oncology, vol.10, issue.6, pp.1025-1034, 2008. ,
DOI : 10.1215/15228517-2008-052
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma, Journal of Clinical Oncology, vol.27, issue.23, pp.3861-3868, 2009. ,
DOI : 10.1200/JCO.2008.20.7944
-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma, Journal of Clinical Oncology, vol.27, issue.8, pp.1262-1269, 2009. ,
DOI : 10.1200/JCO.2008.18.8417
URL : https://hal.archives-ouvertes.fr/in2p3-00460536
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy, Therapeutic Advances in Medical Oncology, vol.70, issue.6, pp.257-67, 2011. ,
DOI : 10.1056/NEJMoa1011418